The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 17th 2024
A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Analysis Identifies Gut Microbiota Affecting Risk of MG
February 29th 2024The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an increased of or protective effect against MG.
Read More
Treatment With iFRC and Ibrutinib Maintenance Led to Durable PFS in Patients With CLL
February 29th 2024In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable remission years after treatment.
Read More
Intravenous Nipocalimab Infusions Safe, Effective Against Autoantibody-Mediated Diseases
February 29th 2024After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter treatment periods and with larger doses.
Read More
Gene Mutations Linked to Adverse Outcomes in AML/MDS
February 28th 2024A rare mutation on the BCL6-corepressor gene correlated with worse overall survival in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, allogenic stem cell transplant improved survival in this population.
Read More
Study Finds Distinct Tumor Microenvironment Characteristics in HBV-Related HCC
February 28th 2024The analysis revealed that viral hepatocellular carcinoma (HCC) had a distinct microbial signature vs non-viral HCC, although only hepatitis B virus–related HCC showed a significantly diverse tumor microbiome.
Read More
Smartphone Tech Reveals Gait Differences in Duchenne Muscular Dystrophy
February 28th 2024Outside of a gait laboratory, this investigation compared gait pattern differences between children who have Duchenne muscular dystrophy (DMD) and their typically developing counterparts to gain more real-world data of DMD-associated gait characteristics.
Read More
What We’re Reading: Alabama IVF Ruling Impacts; Administrative Task Fees; Nursing Shortage Response
February 26th 2024Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.
Read More
Camilla Levister on the Nuances of Designing a Pregnancy-Specific Artificial Pancreas System for T1D
February 24th 2024Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, gives insight into the nuances of testing closed-loop insulin delivery systems for pregnant women.
Watch
The House Democratic Women’s Caucus wrote a letter urging insurers to comply with both contraceptive coverage requirements and recent Biden administration guidance; several pharmacy chains are experiencing disruptions following a hack at Change Healthcare, UnitedHealth’s technology unit; the FDA said it is not planning to take a tougher stance against clinical trial reporting requirement noncompliance.
Read More
30-Day Atorvastatin Improved Brachial Artery FMD in Patients With HFpEF, but More Research Is Needed
February 23rd 2024This study was the first of its kind to explore how taking statin medication affects blood vessel function and exercise response in patients with heart failure with preserved ejection fraction (HFpEF), although the cohort only included 16 patients.
Read More
There Is No Interaction Between BMI and SGLT2 Inhibitor Efficacy in HF, Review Finds
February 23rd 2024Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.
Read More
Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life
February 23rd 2024Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.
Watch
Dr Sudipto Mukherjee: Rethinking Clinical Management for Patients With ISM
February 22nd 2024Population-level data highlight varied risk profiles among patients with indolent systemic mastocytosis (ISM), highlighting the need for individualized treatment approaches, according to Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic.
Watch
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.
Read More
Venetoclax Plus HMA Therapy Shows Encouraging Results in Higher-Risk MDS/CMML
February 22nd 2024Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.
Read More